Effect of recombinant feline interferon‐ω alone and in combination with chemotherapeutic agents on putative tumour‐initiating cells and daughter cells derived from canine and feline mammary tumours

Abstract

Interferons (IFNs) are naturally produced cytokines with multiple important biological functions. The activity of recombinant feline IFN-omega (rFeIFN-omega) alone and in combination with chemotherapeutic drugs was tested on canine and feline mammary carcinoma cell lines (REM134 and CAT-MT) and putative tumour-initiating cells (TIC) derived from these cell lines by sphere assay. Viability was measured by chemoluminescence and a one-way analysis of variance and Student's t-tests were used for statistical analysis. rFeIFN-omega showed in vitro antitumour activity on feline and canine mammary carcinoma cells and putative TICs with a dose-dependent and target cell-specific action. Putative TICs were more resistant to the action of rFeIFN-omega compared with daughter REM134 and CAT-MT cells. REM134 cells and TICs were more sensitive to rFeIFN-omega compared with the feline counterparts. An additive effect was noticed between rFeIFN-omega and conventional anticancer drugs, in particular following co-culture of cells with anthracycline drugs. The results suggest that rFeIFN-omega warrants further investigation as a therapeutic adjunct in feline and canine mammary tumours.